IRVINE, Calif., March 5 /PRNewswire-FirstCall/ -- Edwards Lifesciences Corporation (NYSE: EW), the world leader in the science of heart valves, today announced the first three human implants of the next-generation Edwards transcatheter aortic heart valve, performed by John Webb, M.D., director of the cath lab and cardiac intervention at St. Paul's Hospital in Vancouver, British Columbia.
"Edwards is proud to extend our leadership in this transformational technology with this important development in our transcatheter heart valve program," said Larry L. Wood, Edwards' corporate vice president, transcatheter valve replacement. "We expect to initiate a clinical trial of this new valve in Europe before the end of the year."
Edwards' next-generation balloon-expandable pericardial tissue valve features a cobalt chromium alloy frame that reduces the profile by four to five French. This enables easier access into and within the patient's vasculature for delivery of the valve without open-heart surgery. The new valve will also be offered in additional sizes and builds upon Edwards' more than 20 years of clinical experience and innovation with the most advanced tissue engineering technologies.
"This is a very exciting milestone in the progression of
minimally-invasive valve therapy. The refinements to the new Edwards valve
provide the opportunity to make the transcatheter technology available to
an even broader group of patients suffering from severe aortic stenosis,"
said Webb, who along with his multidisciplinary team has performed more
than 150 transcatheter aortic valve replacement procedures. "Providing
patients and clinicians with a comprehensive selection of treatment
options, including this new valve, can increase the lik
|SOURCE Edwards Lifesciences Corporation|
Copyright©2008 PR Newswire.
All rights reserved